흡입약 시장, 기회, 성장 촉진요인, 산업 동향 분석과 예측(2024-2032년)

The Inhalable Drugs Market, valued at approximately USD 33.4 billion in 2023, is expected to grow at a CAGR of 6.8% between 2024 and 2032. These drugs, delivered directly to the lungs through devices like inhalers, nebulizers, and dry powder inhalers (DPIs), are widely used for treating respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), tuberculosis (TB), and bronchitis. Their rapid absorption and action make them highly effective in addressing respiratory diseases.

The increasing prevalence of respiratory disorders is a key driver of market growth. As the incidence of conditions like asthma and COPD continues to rise, there is a growing demand for innovative treatments and preventive measures. Additionally, advancements in inhalation technology and greater awareness of respiratory conditions are fueling market expansion.

The market is segmented by drug form into aerosol, dry powder, and spray formulations. Dry powder formulations are projected to grow significantly, reaching USD 21.8 billion by 2032. These formulations offer stability due to the absence of liquid solvents or propellants, ensuring longer shelf life and reduced waste. DPIs are also easy to use, portable, and require minimal steps for administration, making them suitable for a wide range of patients, which enhances their popularity and market growth.

By application, the market is divided into respiratory and non-respiratory diseases. In 2023, the respiratory diseases segment dominated the market, contributing USD 24.2 billion. Inhalable drugs provide targeted treatment directly to the lungs, reducing systemic side effects and delivering quicker therapeutic results. Their ability to bypass the digestive system leads to faster absorption and a more immediate response, which is crucial for managing acute respiratory conditions. Inhalable drugs also require smaller doses than oral medications, increasing their bioavailability and efficacy.

Regarding distribution, the market is segmented into hospital pharmacies, retail pharmacies, and online platforms. The hospital pharmacies segment is anticipated to reach USD 25.4 billion by 2032. These pharmacies specialize in the compounding and formulation of inhalable drugs, ensuring precise dosing and high-quality standards for safe and effective treatment.

In the U.S., the inhalable drugs market is expected to reach USD 21.8 billion by 2032, driven by pharmaceutical innovation, robust healthcare infrastructure, and significant investments in research and development (R&D). The U.S. leads in the development of advanced inhalable drug delivery systems, fostering market growth through clinical trials, regulatory approvals, and enhanced patient outcomes.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of respiratory diseases
    • 3.2.1.2 Advancements in inhalation technology
    • 3.2.1.3 Growing awareness and diagnosis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development and production costs
    • 3.2.2.2 Side effects and safety concerns
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
  • 3.5.1 Core technologies
  • 3.5.2 Adjacent technologies
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Form, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Aerosol
• 5.3 Dry powder formulation
• 5.4 Spray

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Respiratory diseases
• 6.3 Non-respiratory diseases

Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospital pharmacies
• 7.3 Retail pharmacies
• 7.4 Online pharmacies

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 AstraZeneca Plc
• 9.2 C.H. Boehringer Sohn AG and Co. KG.
• 9.3 CHIESI Farmaceutici S.p.A.
• 9.4 Cipla Limited
• 9.5 GSK plc
• 9.6 MannKind Corporation
• 9.7 Merck and Co., Inc.
• 9.8 Mundipharma International.
• 9.9 Novartis AG
• 9.10 Pfizer Inc.
• 9.11 PULMATRIX, INC.
• 9.12 Philip Morris International Inc.
• 9.13 Sanofi
• 9.14 Teva Pharmaceutical Industries Ltd.
• 9.15 Viatris Inc.